MRNY ETF — YieldMax MRNA Option Income Strategy ETF

YieldMax MRNA Option Income Strategy ETF (MRNY)

MRNY is an ETF that tracks the Moderna (MRNA). As of August 19, 2026, its distribution rate is 75.37%, its trailing-12-month yield is 91.96%, its expense ratio is 1.00%. Dividend Vision Distribution Safety Score™ is 41/100 (Caution). Fund total return is -43.7% over the past 2.8 years, 22.6 points behind MRNA at -21.1%.

At the current 75.37% distribution rate, a $10,000 investment would generate approximately $7,537 per year, or $628.08 per month on an equivalent basis. Actual weekly payments vary.

MRNY employs a covered call options strategy on Moderna (MRNA) stock, generating income by selling call options against a core equity position. The fund distributes income weekly with a 70.49% annualized distribution rate and charges a 1.00% expense ratio. This strategy appeals to income-focused investors seeking regular cash flow from a concentrated single-stock position, though it caps upside potential and carries the risks associated with options strategies and single-stock exposure.

MRNY performance versus MRNA

Data as of August 19, 2026.

Fund total return is -43.7% over the past 2.8 years, 22.6 points behind MRNA at -21.1%. Its deepest 1-year drawdown was 28.8%.

MRNY key facts

Data as of August 19, 2026.

Distribution Safety Score™

41 · Caution

Safety-Adjusted Yield

30.90%

Issuer

YieldMax

Asset type

ETF

Asset class

Equity

Inception date

10/23/2023

Expense ratio

1.00%

Distribution rate

75.37%

Distribution frequency

Weekly

Trailing yield

91.96%

Last close

$15.60

AUM

$119,423,104

Average volume

69252.0

Last dividend

$0.2261

Ex-dividend date

08/20/2026

Payment date

08/21/2026

Beta

0.0

How Dividend Vision calculates yield and returns

Distribution rate (75.37%) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield (91.96%) is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. We show a 30-day SEC yield when the fund publishes one. Schwab and other issuers may report a TTM distribution yield or SEC yield on a different date — all can be valid; they are not interchangeable. Fund total return uses split-adjusted close with distributions reinvested from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is what the fund did, not your personal gain/loss. Figures below use Dividend Vision data as of August 19, 2026.

Distribution rate methodology · Distribution Safety Score methodology · SEC yield

Sources and review

Data as of August 19, 2026.

Primary sources: YieldMax fund page; Index: Moderna (MRNA); prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MRNY risks and drawbacks

Total return has trailed MRNA over the available window. The deepest 1-year drawdown on record here is 28.8%.

Who may consider MRNY — and who may not

It is a weaker fit for investors whose main goal is matching MRNA total return. This is educational context, not a recommendation to buy or sell.

Compare MRNY

MRNY vs similar funds:

• MRNY vs MRNA

Frequently asked questions

More funds from YieldMax.